Poseida Therapeutics Inc expected to post a loss of 35  cents a share - Earnings Preview

Poseida Therapeutics

07/03/2022 22:33

* Poseida Therapeutics Inc  PSTX.OQ   PSTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 9
(estimated). 
    * The San Diego California-based  company is expected to
report
revenue of $15.833 million, according to the mean estimate from
3 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Poseida
Therapeutics Inc
is for a loss of 35 cents per share. For the same quarter last
year, the company reported a loss of 58 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $21.5​, about 84.7% above​ its last closing
price of $3.30. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.74       -0.74      -0.68     Beat    8.5
 Jun. 30 2021  -0.63       -0.63      -0.74     Missed  -17.5
 Mar. 31 2021  -0.64       -0.63      -0.62     Beat    2.4​
 Dec. 31 2020  -0.69       -0.69      -0.58     Beat    15.5
 ​​Sep.        -0.55       -0.55      -0.63     Missed  -14.5
 30 2020                                                
 Jun. 30 2020  -1.48       -1.48      -2.28     Missed  -54.1​
 This summary was machine generated March 7 at 22:33 GMT.  All
figures in US dollars  unless otherwise stated